SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ — Shares of BioAge (NASDAQ: BIOA) have plummeted since the company’s December 6 announcement of the discontinuation of a Phase 2 trial for its weight-loss drug azelaprag due to safety concerns. The abrupt halt comes just a little over two months…